Ampersand Biosciences Secures $65M Series B to Accelerate Next-Gen Luminex and Protein Biomarker Innovations

Ampersand Biosciences is thrilled to announce a monumental milestone in its journey with a recent funding round that has raised $65 million—a sum that underscores the strong investor confidence in the company’s expertise and future potential. With decades of experience in developing and validating cutting‐edge Luminex based assays, Ampersand Biosciences has built a solid reputation as a trusted GLP lab specializing in protein biomarker sample testing. This significant infusion of capital is set to accelerate the company’s ambitious plans to enhance its portfolio of diagnostic solutions and expand its research and development efforts. The funding will primarily be directed toward advancing proprietary assay technologies, optimizing laboratory operations, and broadening the company’s reach into additional markets where precise biomarker detection is critical for early disease diagnosis and treatment monitoring. Moreover, this investment will allow the teams at Ampersand Biosciences to invest further in talent acquisition and state-of-the-art infrastructure, ensuring that the company remains at the forefront of innovation in the biomedical field. As researchers and clinicians increasingly rely on high-quality diagnostic assays to drive patient care and research breakthroughs, Ampersand Biosciences is uniquely positioned to meet these demands with unparalleled rigor and scientific integrity. This funding not only validates the legacy of technical excellence at the company but also catalyzes its future growth, paving the way for transformative advancements that could redefine standards in protein biomarker testing and Luminex assay performance. The entire team celebrates this achievement and eagerly anticipates the new opportunities and groundbreaking initiatives that this investment will bring.